This project was completed by Intensity. Intensity joined Secretariat on February 1, 2023.
Intensity determined the extent to which certain patents in the field of molecular diagnostics were unenforceable due to prosecution laches. Intensity also performed an analysis of damages relating to alleged infringement of patented technology by quantifying reasonable royalties.
Intensity was retained to analyze the ongoing investments, marketing, and research in a biotechnology company specializing in molecular diagnostics. Intensity assessed the extent to which these were or were not sunk costs and the extent to which these costs precluded alternative research and investment spending. Intensity then determined a reasonable and market-based royalty for technology as part of molecular diagnostics testing kits, based on consideration of the market for these kits, the licensing policies and histories of both companies, product sales and profitability.
Intensity also performed an analysis of damages relating to alleged infringement of patented technology by quantifying reasonable royalties based on consideration of relevant licensing agreements, accused sales and profitability, and the unique contribution of the patented technology.
Economic issues include apportionment, licensing, and reasonable royalties.
Secretariat Experts Lead the Field in Lexology’s 2025 Thought Leaders – Arbitration Report
Secretariat has earned the top position in the Lexology Index Thought Leaders – Arbitration 2025 report, with the most experts listed in the rankings, and highest number of Global Elite Thought Leaders. The Lexology Index Thought Leaders – Arbitration report is a highly respected publication that spotlights the world’s foremost arbitrators, legal counsel, and […]
Expert Economic Testimony Plays Crucial Role in Puerto Rico Healthcare Antitrust Case
Director Jason Albert provided pivotal testimony in Roberto Vázquez-Ramos, et al. v. Triple-S Salud, et al., which examined allegations of unfair competition and monopolistic practices involving exclusive provider arrangements under Puerto Rico’s government health plan. In May 2019, the Plaintiffs—a group of urologists in Puerto Rico’s Western Region—alleged that Triple-S Salud (“Triple-S”), the region’s government […]
Navigating ECCTA: A Guide for Organizations
Ben Boorer, writing for Enterprise Times, discusses the Economic Crime and Corporate Transparency Act (ECCTA), which comes into force on 1st September 2025. ECCTA will reshape the UK’s compliance landscape by, amongst other things, holding organisations accountable for fraud committed by employees, agents, and subsidiaries.